Role of Immunotherapy in Patients with NSCLC: Emerging Biomarkers

home / insights / role-of-immunotherapy-in-patients-with-nsclc-emerging-biomarkers

Expert oncologist Martin Dietrich, MD, PhD, shares his excitement for an upcoming program wherein he and Meghan Mooradian, MD, highlight the evolving role of immunotherapy and biomarker-driven therapy in non-small cell lung cancer.

Experts on lung cancer

EP. 1: The Role of Molecular Testing In Metastatic NSCLC

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
January 23rd 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

Experts on lung cancer

EP. 2: Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
January 23rd 2023

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

Experts on breast cancer

EP. 3: Applying Molecular Biomarkers in Treatment Decision Making in NSCLC

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
January 30th 2023

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

Experts on breast cancer

EP. 4: Clinical Insights on the Role of PD-1/PD-L1 Inhibitors in NSCLC

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
January 30th 2023

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

Meghan J. Mooradian, MD, an expert on lung cancer

EP. 5: Treatment Approaches for NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
February 6th 2023

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Martin Dietrich, MD, PhD, an expert on lung cancer

EP. 6: Immunotherapy in NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
February 6th 2023

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Meghan J. Mooradian, MD, an expert on lung cancer

EP. 7: NSCLC: Discussing Molecular Biomarkers and Treatment Decisions with Patients

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
February 13th 2023

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

Experts on lung cancer

EP. 8: Future Perspectives in Biomarker Testing and Targeted Therapy in NSCLC

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
February 13th 2023

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

Experts on lung cancer

EP. 9: Emerging Concepts on the Role of Immunotherapy in NSCLC

Martin Dietrich, MD, PhD;Meghan J. Mooradian, MD
February 20th 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.